BIOMARKER:

KIT mutation

A2 | Sensitive

B | Sensitive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

A2 | Resistant

B | Resistant

C2 | Resistant

C3 | Resistant

D | Resistant

Melanoma

Gastrointestinal Stromal Tumor

Acute Myelogenous Leukemia

Thymic Carcinoma

Mucosal Melanoma

Cutaneous Melanoma

Non Small Cell Lung Cancer

Prostate Cancer

sunitinib

KIT mutation|Thymic Carcinoma|sunitinib

KIT mutation|Melanoma|sunitinib

HIA + azacitidine

KIT mutation|Acute Myelogenous Leukemia|HIA + azacitidine

pimitespib

KIT mutation|Gastrointestinal Stromal Tumor|pimitespib

HAG + azacitidine

KIT mutation|Acute Myelogenous Leukemia|HAG + azacitidine

imatinib

KIT mutation|Melanoma|imatinib

KIT mutation|Gastrointestinal Stromal Tumor|imatinib

KIT mutation|Cutaneous Melanoma|imatinib

HDA + azacitidine

KIT mutation|Acute Myelogenous Leukemia|HDA + azacitidine

ripretinib

KIT mutation|Melanoma|ripretinib

KIT mutation|Gastrointestinal Stromal Tumor|ripretinib

avapritinib

KIT mutation|Gastrointestinal Stromal Tumor|avapritinib

KIT mutation|Acute Myelogenous Leukemia|avapritinib

cisplatin + dacarbazine

KIT mutation|Mucosal Melanoma|cisplatin + dacarbazine

nivolumab

KIT mutation|Melanoma|nivolumab

regorafenib

KIT mutation|Melanoma|regorafenib

sunitinib + PLX9486

KIT mutation|Gastrointestinal Stromal Tumor|sunitinib + PLX9486

LY3009120

KIT mutation|Acute Myelogenous Leukemia|LY3009120

temozolomide

KIT mutation|Mucosal Melanoma|temozolomide

temozolomide + rivoceranib

KIT mutation|Melanoma|temozolomide + rivoceranib

imatinib + toripalimab-tpzi

KIT mutation|Melanoma|imatinib + toripalimab-tpzi

cabozantinib tablet

KIT mutation|Acute Myelogenous Leukemia|cabozantinib tablet

ivosidenib

KIT mutation|Acute Myelogenous Leukemia|ivosidenib

enzalutamide capsule

KIT mutation|Prostate Cancer|enzalutamide capsule

enzalutamide capsule + abiraterone acetate

KIT mutation|Prostate Cancer|enzalutamide capsule + abiraterone acetate

abiraterone acetate

KIT mutation|Prostate Cancer|abiraterone acetate

AZD1775 + avapritinib

KIT mutation|Gastrointestinal Stromal Tumor|AZD1775 + avapritinib

PD1 inhibitor

KIT mutation|Melanoma|PD1 inhibitor

KIT mutation|Mucosal Melanoma|PD1 inhibitor

KIT mutation|Cutaneous Melanoma|PD1 inhibitor

KIT mutation|Non Small Cell Lung Cancer|PD1 inhibitor

Immunotherapy

KIT mutation|Non Small Cell Lung Cancer|Immunotherapy